Lytic and latent EBV gene expression in transplant recipients with and without post-transplant lymphoproliferative disorder

Journal of Clinical Virology

Volumn 52, Issue 3, 2011, Pages 231-235

  Kroll, Jing ^a   Li, Shaobing ^a   Levi, Marilyn ^a   Weinberg, Adriana ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Epstein Barr virus; Hematopoietic stem cell transplant; Post transplant lymphoproliferative disorder

Indexed keywords

GENE PRODUCT; IMMEDIATE EARLY PROTEIN BZLF1; LMP 2A PROTEIN; MESSENGER RNA; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS PROTEIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; EPSTEIN BARR VIRUS; FEMALE; GENE EXPRESSION; GRAFT RECIPIENT; HOSPITAL PATIENT; HUMAN; IMMUNOCOMPETENCE; LYMPHOPROLIFERATIVE DISEASE; MALE; POST TRANSSSPLANT LYMPHOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; PROSPECTIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; VIRUS EXPRESSION; VIRUS GENE; VIRUS PATHOGENESIS; VIRUS REPLICATION;

ADULT; AGED; AGED, 80 AND OVER; DNA, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; RNA, MESSENGER; TRANSPLANTATION; VIRAL LOAD; VIRUS LATENCY;

EID: 80054695450     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2011.06.013     Document Type: Article

References (41)

1. Brunstein C.G., Weisdorf D.J., DeFor T., Barker J.N., Tolar J., van Burik J.A., et al. Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation. Blood 2006, 108:2874-2880.
2. Comoli P., Basso S., Zecca M., Pagliara D., Baldanti F., Bernardo M.E., et al. Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation. Am J Transplant 2007, 7:1648-1655.
3. Hale G., Waldmann H. Risks of developing Epstein-Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants CAMPATH Users. Blood 1998, 91:3079-3083.
4. Peniket A.J., Perry A.R., Williams C.D., MacMillan A., Watts M.J., Isaacson P.G., et al. A case of EBV-associated lymphoproliferative disease following high-dose therapy and CD34-purified autologous peripheral blood progenitor cell transplantation. Bone Marrow Transplant 1998, 22:307-309.
5. Sundin M., Le Blanc K., Ringden O., Barkholt L., Omazic B., Lergin C., et al. The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation. Haematologica 2006, 91:1059-1067.
6. van Esser J.W., van der Holt B., Meijer E., Niesters H.G., Trenschel R., Thijsen S.F., et al. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT. Blood 2001, 98:972-978.
7. Zutter M.M., Martin P.J., Sale G.E., Shulman H.M., Fisher L., Thomas E.D., et al. Epstein-Barr virus lymphoproliferation after bone marrow transplantation. Blood 1988, 72:520-529.
8. Libertiny G., Watson C.J., Gray D.W., Welsh K.I., Morris P.J. Rising incidence of post-transplant lymphoproliferative disease in kidney transplant recipients. Br J Surg 2001, 88:1330-1334.
9. Mihalov M.L., Gattuso P., Abraham K., Holmes E.W., Reddy V. Incidence of post-transplant malignancy among 674 solid-organ-transplant recipients at a single center. Clin Transplant 1996, 10:248-255.
10. Swinnen L.J., Costanzo-Nordin M.R., Fisher S.G., O'Sullivan E.J., Johnson M.R., Heroux A.L., et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med 1990, 323:1723-1728.
11. Bernard F., Sarran N., Margueritte G., Barneon G., Astruc J. Successful treatment of an Epstein-Barr virus-associated B-cell lymphoproliferative disease in a child with acute lymphoblastic leukemia using an anti-CD20 monoclonal antibody. Med Pediatr Oncol 2001, 36:329-331.
12. Choquet S., Leblond V., Herbrecht R., Socie G., Stoppa A.M., Vandenberghe P., et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood 2006, 107:3053-3057.
13. Elstrom R.L., Andreadis C., Aqui N.A., Ahya V.N., Bloom R.D., Brozena S.C., et al. Treatment of PTLD with rituximab or chemotherapy. Am J Transplant 2006, 6:569-576.
14. Milpied N., Vasseur B., Parquet N., Garnier J.L., Antoine C., Quartier P., et al. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann Oncol 2000, 11(Suppl. 1):113-116.
15. Oertel S.H., Verschuuren E., Reinke P., Zeidler K., Papp-Vary M., Babel N., et al. Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Am J Transplant 2005, 5:2901-2906.
16. Styczynski J., Einsele H., Gil L., Ljungman P. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases. Transpl Infect Dis 2009, 11:383-392.
17. Trappe R.U., Choquet S., Reinke P., Dreyling M., Mergenthaler H.G., Jager U., et al. Salvage therapy for relapsed posttransplant lymphoproliferative disorders (PTLD) with a second progression of PTLD after Upfront chemotherapy: the role of single-agent rituximab. Transplantation 2007, 84:1708-1712.
18. Yang J., Tao Q., Flinn I.W., Murray P.G., Post L.E., Ma H., et al. Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response. Blood 2000, 96:4055-4063.
19. Zilz N.D., Olson L.J., McGregor C.G. Treatment of post-transplant lymphoproliferative disorder with monoclonal CD20 antibody (rituximab) after heart transplantation. J Heart Lung Transplant 2001, 20:770-772.
20. Curtis R.E., Travis L.B., Rowlings P.A., Socie G., Kingma D.W., Banks P.M., et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood 1999, 94:2208-2216.
21. Leblond V., Sutton L., Dorent R., Davi F., Bitker M.O., Gabarre J., et al. Lymphoproliferative disorders after organ transplantation: a report of 24 cases observed in a single center. J Clin Oncol 1995, 13:961-968.
22. Newell K.A., Alonso E.M., Whitington P.F., Bruce D.S., Millis J.M., Piper J.B., et al. Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression. Transplantation 1996, 62:370-375.
23. Abderrahim E., Harzallah A., Barbouch S., Turki S., Helal I., Ben Abdallah T., et al. Lymphoproliferative disorders in kidney transplant recipients: incidence, clinical characteristics and outcome. Rev Med Intern 2008, 29:535-540.
24. Jabs W.J., Hennig H., Kittel M., Pethig K., Smets F., Bucsky P., et al. Normalized quantification by real-time PCR of Epstein-Barr virus load in patients at risk for posttransplant lymphoproliferative disorders. J Clin Microbiol 2001, 39:564-569.
25. Rose C., Green M., Webber S., Kingsley L., Day R., Watkins S., et al. Detection of Epstein-Barr virus genomes in peripheral blood B cells from solid-organ transplant recipients by fluorescence in situ hybridization. J Clin Microbiol 2002, 40:2533-2544.
26. Hopwood P.A., Brooks L., Parratt R., Hunt B.J., Bokhari M., Thomas J.A., et al. Persistent Epstein-Barr virus infection: unrestricted latent and lytic viral gene expression in healthy immunosuppressed transplant recipients. Transplantation 2002, 74:194-202.
27. Zawilinska B., Kosinska A., Lenart M., Kopec J., Piatkowska-Jakubas B., Skotnicki A., et al. Detection of specific lytic and latent transcripts can help to predict the status of Epstein-Barr virus infection in transplant recipients with high virus load. Acta Biochim Pol 2008, 55:693-699.
28. Jesser R.D., Li S., Weinberg A. Regulatory T cells generated during cytomegalovirus in vitro stimulation of mononuclear cells from HIV-infected individuals on HAART correlate with decreased lymphocyte proliferation. Virology 2006, 352:408-417.
29. Ma S.D., Hegde S., Young K.H., Sullivan R., Rajesh D., Zhou Y., et al. A new model of Epstein-Barr virus infection reveals an important role for early lytic viral protein expression in the development of lymphomas. J Virol 2011, 85:165-177.
30. Datta A.K., Colby B.M., Shaw J.E., Pagano J.S. Acyclovir inhibition of Epstein-Barr virus replication. Proc Natl Acad Sci USA 1980, 77:5163-5166.
31. Pirsch J.D., Stratta R.J., Sollinger H.W., Hafez G.R., D'Alessandro A.M., Kalayoglu M., et al. Treatment of severe Epstein-Barr virus-induced lymphoproliferative syndrome with ganciclovir: two cases after solid organ transplantation. Am J Med 1989, 86:241-244.
32. Hanto D.W. Classification of Epstein-Barr virus-associated posttransplant lymphoproliferative diseases: implications for understanding their pathogenesis and developing rational treatment strategies. Annu Rev Med 1995, 46:381-394.
33. Oertel S.H., Ruhnke M.S., Anagnostopoulos I., Kahl A.A., Frewer A.F., Bechstein W.O., et al. Treatment of Epstein-Barr virus-induced posttransplantation lymphoproliferative disorder with foscarnet alone in an adult after simultaneous heart and renal transplantation. Transplantation 1999, 67:765-767.
34. Schmidt W., Anagnostopoulos I., Scherubl H. Virostatic therapy for advanced lymphoproliferation associated with the Epstein-Barr virus in an HIV-infected patient. N Engl J Med 2000, 342:440-441.
35. McDiarmid S.V., Jordan S., Kim G.S., Toyoda M., Goss J.A., Vargas J.H., et al. Prevention and preemptive therapy of posttransplant lymphoproliferative disease in pediatric liver recipients. Transplantation 1998, 66:1604-1611.
36. Darenkov I.A., Marcarelli M.A., Basadonna G.P., Friedman A.L., Lorber K.M., Howe J.G., et al. Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy. Transplantation 1997, 64:848-852.
37. Hoshino Y., Katano H., Zou P., Hohman P., Marques A., Tyring S.K., et al. Long-term administration of valacyclovir reduces the number of Epstein-Barr virus (EBV)-infected B cells but not the number of EBV DNA copies per B cell in healthy volunteers. J Virol 2009, 83:11857-11861.
38. Kenagy D.N., Schlesinger Y., Weck K., Ritter J.H., Gaudreault-Keener M.M., Storch G.A. Epstein-Barr virus DNA in peripheral blood leukocytes of patients with posttransplant lymphoproliferative disease. Transplantation 1995, 60:547-554.
39. Baldanti F., Grossi P., Furione M., Simoncini L., Sarasini A., Comoli P., et al. High levels of Epstein-Barr virus DNA in blood of solid-organ transplant recipients and their value in predicting posttransplant lymphoproliferative disorders. J Clin Microbiol 2000, 38:613-619.
40. Rowe D.T., Qu L., Reyes J., Jabbour N., Yunis E., Putnam P., et al. Use of quantitative competitive PCR to measure Epstein-Barr virus genome load in the peripheral blood of pediatric transplant patients with lymphoproliferative disorders. J Clin Microbiol 1997, 35:1612-1615.
41. Savoie A., Perpete C., Carpentier L., Joncas J., Alfieri C. Direct correlation between the load of Epstein-Barr virus-infected lymphocytes in the peripheral blood of pediatric transplant patients and risk of lymphoproliferative disease. Blood 1994, 83:2715-2722.